In an independent study, we proposed that the drug acetazolamide which targets the genes CA2 and CA4, having known interactions with the cilia genes, DYNLL1 and CDK3 respectively, may be repurposed for schizophrenia based on negative correlation of drug-induced versus disease-associated gene expression profiles and other biological evidences95. This evidence concerns the gene DYNLL1 and schizophrenia.